HCV Guidance Updates - Recommendations Reflecting Vosevi and Mavyret

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) with the International Antiviral Society developed a living document with ever evolving guidelines to treat HCV.

The guidelines have a complex algorithm for practitioners around the country to follow and see what's the right treatment, for the right patients, for the right about of time. The document is beneficial for patients as well living with or treating HCV. When new HCV drugs are approved, and new real world data is established, the guidelines are updated.

What’s New, Updates, and Changes to the Guidance

Thursday, September 21, 2017
This version of the guidance has been updated to reflect several important developments, including the recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. Updated recommendations reflecting these approvals are provided throughout the guidance.

Updated references have been provided throughout the guidance.

In addition to updates to all the sections, the following new sections have been added to the guidance:

• HCV Resistance Primer
• Kidney Transplant Patients
• HCV in Pregnancy
• HCV in Children

Genotype 1 & 3
New Treatment-Naïve & Treatment-Experienced
The following pages include guidance for management of treatment-naive patients.

• Genotype 1
• Genotype 2
• Genotype 3
• Genotype 4
• Genotype 5 or 6

The following pages include guidance for management of treatment-experienced patients.

• Genotype 1
• Genotype 2
• Genotype 3
• Genotype 4
• Genotype 5 or 6

Stay current with all guideline updates, "click here."

Complete Guidance
Download the PDF
Version: September 21, 2017